EPISODE · Jan 26, 2023 · 20 MIN
The End of Humira’s $200 Billion Drug Monopoly
from Tradeoffs
After 20 years, Humira – the best selling drug of all time – is finally facing direct competition. Typically, once generic drugs arrive on a market they dominate sales and deliver big savings. But Humira’s competitors, known as biosimilars, aren’t like most other generics.This week, what makes this prescription drug showdown so unusual – and so important.Guest:Marta Wosińska, PhD, Visiting Fellow, Brookings InstitutionLearn more and read a full transcript on our website.Want more Tradeoffs? Sign up for our free weekly newsletter featuring the latest health policy research and news.Support this type of journalism today, with a gift. Hosted on Acast. See acast.com/privacy for more information.
What this episode covers
After 20 years, Humira – the best selling drug of all time – is finally facing direct competition. Typically, once generic drugs arrive on a market they dominate sales and deliver big savings. But Humira’s competitors, known as biosimilars, aren’t like most other generics.This week, what makes this prescription drug showdown so unusual – and so important.Guest:Marta Wosińska, PhD, Visiting Fellow, Brookings InstitutionLearn more and read a full transcript on our website.Want more Tradeoffs? Sign up for our free weekly newsletter featuring the latest health policy research and news.Support this type of journalism today, with a gift. Hosted on Acast. See acast.com/privacy for more information.
NOW PLAYING
The End of Humira’s $200 Billion Drug Monopoly
No transcript for this episode yet
Similar Episodes
Jun 24, 2026 ·58m
Jun 23, 2026 ·45m
Jun 22, 2026 ·28m